Suppression of recurrent Herpes simplex infection in HIV

Suppression of recurrent Herpes simplex infection in HIV refers to continuous, long-term antiviral management aimed at preventing repeated symptomatic outbreaks and asymptomatic viral shedding of herpes simplex virus (HSV-1 or HSV-2) in individuals co-infected with human immunodeficiency virus

Suppression of recurrent Herpes simplex infection in HIV refers to continuous, long-term antiviral management aimed at preventing repeated symptomatic outbreaks and asymptomatic viral shedding of herpes simplex virus (HSV-1 or HSV-2) in individuals co-infected with human immunodeficiency virus Clinical management focuses on mitigating severe mucocutaneous morbidity, reducing secondary superinfections, and preventing tissue necrosis or disseminated disease in this immunocompromised population

Due to impaired cell-mediated immunity—often correlated with lower CD4+ T-cell counts—people with HIV experience significantly higher rates of reactivation, prolonged viral replication, and more painful, extensive, or non-healing anogenital and orolabial ulcerations

Due to impaired cell-mediated immunity—often correlated with lower CD4+ T-cell counts—people with HIV experience significantly higher rates of reactivation, prolonged viral replication, and more painful, extensive, or non-healing anogenital and orolabial ulcerations Clinical management focuses on mitigating severe mucocutaneous morbidity, reducing secondary superinfections, and preventing tissue necrosis or disseminated disease in this immunocompromised population

Due to impaired cell-mediated immunity—often correlated with lower CD4+ T-cell counts—people with HIV experience significantly higher rates of reactivation, prolonged viral replication, and more painful, extensive, or non-healing anogenital and orolabial ulcerations